Nolato

* Adj. EBITA SEK 274m (+4% vs. ABG, +2% vs. IR consensus)* We expect consensus adj. EBITA to come up by 1-2%* 14.5x '26e EV/EBITA on pre-Q3 estimates (and on yesterday's close)Q3 outcomeSales came in at SEK 2,342m (+1% vs. ABG 2,324m, 0% vs. IR cons ...

* Q3e: Medical stable, but negative seasonality* EBITA estimates cut by 2-3%, mainly for Engineered* Share trading at 14x '26e EV/EBITAQ3e: stable Medical, but a seasonal drop in marginsWe expect Nolato will report Q3 net sales of SEK 2,324m, down 3%...

Another impressive margin lift Nolato reported Q2 EBITA 5% and 7% above ABGSCe and IR consensus, respectively. The beat was broad-based, with better organic growth (2pp above ABGSCe), a better EBITA margin (0.4pp above ABGSCe, 0.6pp above cons), and ...

Q2 outcome Sales was SEK 2,395m (+2% vs. ABG 2,345m, +2% vs. IR cons 2,351m), down 2% y-o-y, although organic growth was +4% (ABG +2%). EBITA came in at SEK 277m (+5% vs ABG 264m, +7% vs. cons 259m), for an EBITA margin of 11.6% (ABG 11.2%, cons 11.0...

Q2e: FX headwinds, but continued strong margins We expect Nolato to report Q2 net sales of SEK 2,345m, a y-o-y decline of 4%, of which +2% is organic and -6% from FX, driven mainly by the weaker USD. Following its CMD on 13 March, when Nolato raised ...

Impressive margin lift in both segments, EBITA +6% vs. cons We raise EBITA by 4-1%, of which -1pp from FX 16-14x '25e-'26e EV/EBITA, 60% of EBITA non-cyclical Medical Impressive margin lift in both segments Nolato reported Q1 sales 2% below Modular Finance...

EBITA SEK 271m (+3% vs. ABG, +6% vs. IR cons) We expect cons EBITA upgrades of 3-4% for '25e 15-13x '25e-'26e EV/EBITA on pre-Q1 estimates Q1 outcome Sales came in at SEK 2,453m (-3% vs. ABG SEK 2,527m, -2% vs. Modular Finance IR cons SEK 2,494m), up...